Doxorubicin-polyglycerol-nanodiamond composites stimulate glioblastoma cell immunogenicity through activation of autophagy

被引:61
作者
Li, Tong-Fei [1 ,2 ]
Xu, Yong-Hong [3 ]
Li, Ke [4 ]
Wang, Chao [1 ,2 ]
Liu, Xin [1 ,2 ]
Yue, Yuan [1 ,2 ]
Chen, Zhuo [1 ,2 ]
Yuan, Shen-Jun [1 ,2 ]
Wen, Yu [1 ,2 ]
Zhang, Quan [1 ,2 ]
Han, Min [5 ]
Komatsu, Naoki [6 ]
Zhao, Li [7 ,8 ]
Chen, Xiao [1 ,2 ]
机构
[1] Wuhan Univ, Dept Pharmacol, Sch Basic Med Sci, Donghu Ave 185, Wuhan 430072, Peoples R China
[2] Hubei Prov Key Lab Dev Originated Dis, Wuhan 430071, Peoples R China
[3] Wuhan Univ, Inst Ophthalmol Res, Dept Ophthalmol, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China
[4] Wuhan Univ, Demonstrat Ctr Expt Basic Med Educ, Sch Basic Med Sci, Donghu Ave 185, Wuhan 430072, Peoples R China
[5] Huazhong Univ Sci & Technol, Tongji Hosp, Div Nephrol, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China
[6] Kyoto Univ, Grad Sch Human & Environm Studies, Sakyo Ku, Kyoto 6068501, Japan
[7] Soochow Univ, Sch Radiat Med & Protect, State Key Lab Radiat Med & Protect, Suzhou 215123, Jiangsu, Peoples R China
[8] Soochow Univ, Sch Radiol & Interdisciplinary Sci RAD X, Collaborat Innovat Ctr Radiat Med, Jiangsu Higher Educ Inst, Suzhou 215123, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Nanodiamond; Doxorubicin; Glioblastoma; Immunogenicity; Autophagy; CROSS-PRESENTATION; DENDRITIC CELLS; DUAL ROLE; DEATH; INHIBITION; MODULATION; MECHANISMS; INDUCTION; APOPTOSIS; PROTEINS;
D O I
10.1016/j.actbio.2019.01.020
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Immunosuppression is a salient feature of GBM associated with the disease's grim prognosis and the limited success of anti-GBM immunotherapy. Stimulating immunogenicity of the GBM cells (GC) is a promising approach to subverting the GBM-associated immunosuppression. We had previously devised a drug composite based on polyglycerol-functionalized nanodiamonds bearing doxorubicin (Nano-DOX) and demonstrated that Nano-DOX effectively modulated GBM's immunosuppressive microenvironment through stimulating the immunogenicity of GC and initiated anti-GBM immune responses. The present study now explored the mechanism of Nano-DOX's immunostimulatory action. Nano-DOX was found to induce autophagy rather than apoptosis in GC and stimulated GC to emit antigens and damage associated molecular patterns (DAMPs) that are potent adjuvants, which resulted in enhanced activation of dendritic cells (DC). Heightened autophagosome release was observed in Nano-DOX-treated GC but was shown not to be a major channel of antigen donation. Blocking autophagy in GC not only reduced Nano-DOX-stimulated GC antigen donation and DAMPs emission, but also efficiently attenuated DC activation stimulated by Nano-DOX-treated GC. Taken together, these findings suggest that activation of autophagy is a central mechanism whereby Nano-DOX stimulates GC's immunogenicity. Our work provides new insight on how nanotechnology can be applied to therapeutically modulate the GBM immune microenvironment by harnessing autophagy in the cancer cells. Statement of Significance Immunosuppression is a salient feature of GBM associated with the grim prognosis of the disease and the limited success of anti-GBM immunotherapy. We demonstrated that Doxorubicin-polyglycerol-nanodia mond composites could activate autophagy in GBM cells and thereby stimulate the immunogenecity of GBM cells. This discovery 1, sheds new light on how nanotechnology could be applied to therapeutically modulate the tumor immune microenvironment, and 2, provides a powerful tool for subverting the GBM's immunosuppressive microenvironment, which has great therapeutic potential for the treatment of GBM. (C) 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:381 / 394
页数:14
相关论文
共 49 条
  • [11] Jackson C. M., 2018, CLIN CANCER RES
  • [12] Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model
    Jacobs, Valerie L.
    Valdes, Pablo A.
    Hickey, William F.
    De Leo, Joyce A.
    [J]. ASN NEURO, 2011, 3 (03): : 171 - 181
  • [13] Immunogenic Cell Death in Cancer Therapy
    Kroemer, Guido
    Galluzzi, Lorenzo
    Kepp, Oliver
    Zitvogel, Laurence
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, VOL 31, 2013, 31 : 51 - 72
  • [14] Immunogenic cell death and DAMPs in cancer therapy
    Krysko, Dmitri V.
    Garg, Abhishek D.
    Kaczmarek, Agnieszka
    Krysko, Olga
    Agostinis, Patrizia
    Vandenabeele, Peter
    [J]. NATURE REVIEWS CANCER, 2012, 12 (12) : 860 - 875
  • [15] Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma
    Li, Tong-Fei
    Li, Ke
    Zhang, Quan
    Wang, Chao
    Yue, Yuan
    Chen, Zhuo
    Yuan, Shen-Jun
    Liu, Xin
    Wen, Yu
    Han, Min
    Komatsu, Naoki
    Xu, Yong-Hong
    Zhao, Li
    Chen, Xiao
    [J]. BIOMATERIALS, 2018, 181 : 35 - 52
  • [16] Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment
    Li, Tong-Fei
    Li, Ke
    Wang, Chao
    Liu, Xin
    Wen, Yu
    Xu, Yong-Hong
    Zhang, Quan
    Zhao, Qiu-Ya
    Shao, Ming
    Li, Yan-Ze
    Han, Min
    Komatsu, Naoki
    Zhao, Li
    Chen, Xiao
    [J]. JOURNAL OF CONTROLLED RELEASE, 2017, 268 : 128 - 146
  • [17] Efficient cross-presentation depends on autophagy in tumor cells
    Li, Yuhuan
    Wang, Li-Xin
    Yang, Guojun
    Hao, Fang
    Urba, Walter J.
    Hu, Hong-Ming
    [J]. CANCER RESEARCH, 2008, 68 (17) : 6889 - 6895
  • [18] The Vitamin E Analogue α-TEA Stimulates Tumor Autophagy and Enhances Antigen Cross-Presentation
    Li, Yuhuan
    Hahn, Tobias
    Garrison, Kendra
    Cui, Zhi-Hua
    Thorburn, Andrew
    Thorburn, Jacqueline
    Hu, Hong-Ming
    Akporiaye, Emmanuel T.
    [J]. CANCER RESEARCH, 2012, 72 (14) : 3535 - 3545
  • [19] Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
    Li, Yuhuan
    Wang, Li-Xin
    Pang, Puiyi
    Cui, Zhihua
    Aung, Sandra
    Haley, Daniel
    Fox, Bernard A.
    Urba, Walter J.
    Hu, Hong-Ming
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (22) : 7047 - 7057
  • [20] Lieberman Frank, 2017, F1000Res, V6, P1892, DOI 10.12688/f1000research.11493.1